COGT
Cogent Biosciences, Inc. NASDAQ Listed Mar 29, 2018$35.87
Mkt Cap $5.8B
52w Low $4.55
79.9% of range
52w High $43.73
50d MA $36.49
200d MA $27.75
P/E (TTM)
-14.4x
EV/EBITDA
-7.1x
P/B
3.9x
Debt/Equity
0.4x
ROE
-51.7%
P/FCF
-9.0x
RSI (14)
—
ATR (14)
—
Beta
0.47
50d MA
$36.49
200d MA
$27.75
Avg Volume
2.0M
About
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tu…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | BMO | -0.51 | -0.55 | -7.8% | 37.62 | +1.0% | +1.9% | +1.9% | +1.9% | -0.7% | -1.5% | — |
| Nov 7, 2025 | BMO | -0.54 | -0.50 | +7.4% | 14.82 | +121.1% | +119.0% | +119.0% | +125.5% | +137.9% | +128.3% | — |
| Aug 5, 2025 | BMO | -0.55 | -0.53 | +3.6% | 11.36 | -2.7% | -3.4% | -3.4% | -4.4% | -3.5% | -3.8% | — |
| May 6, 2025 | BMO | -0.56 | -0.52 | +7.1% | 4.70 | -1.1% | +0.4% | +0.4% | +6.0% | +2.3% | +9.1% | — |
| Feb 25, 2025 | BMO | -0.59 | -0.09 | +84.7% | 6.99 | +3.3% | -4.0% | -4.0% | +0.0% | +7.7% | +0.1% | — |
| Nov 12, 2024 | BMO | -0.55 | -0.64 | -16.4% | 10.38 | +0.0% | +0.2% | +0.2% | -7.0% | -14.3% | -13.4% | — |
| Aug 6, 2024 | BMO | -0.55 | -0.59 | -7.3% | 9.26 | -0.6% | -6.8% | -6.8% | -4.0% | -7.3% | -8.2% | — |
| May 7, 2024 | BMO | -0.50 | -0.62 | -24.0% | 7.76 | -0.1% | -2.1% | -2.1% | +2.1% | -2.6% | -5.3% | — |
| Feb 26, 2024 | BMO | -0.54 | -0.63 | -16.7% | 7.50 | +4.7% | -0.1% | -0.1% | -2.1% | -6.7% | -3.6% | — |
| Nov 2, 2023 | BMO | -0.50 | -0.64 | -28.0% | 8.56 | +1.6% | -0.6% | -0.6% | -2.5% | -0.7% | -14.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $35.68 | $35.68 | +0.0% | -0.7% | -3.7% | -3.0% | -6.4% | -0.8% |
| Feb 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $37.62 | $38.00 | +1.0% | +1.9% | +1.9% | -0.7% | -1.5% | +4.1% |
| Jan 21 | Wedbush | Maintains | Outperform → Outperform | — | $39.90 | $39.96 | +0.2% | +0.0% | -0.9% | -8.1% | -5.1% | -3.5% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.26 | $34.46 | +0.6% | +1.5% | +5.9% | +3.8% | +3.2% | +1.5% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $37.90 | $38.58 | +1.8% | +4.4% | +3.8% | +6.0% | +4.8% | +2.6% |
| Dec 8 | Needham | Maintains | Hold → Hold | — | $38.77 | $43.07 | +11.1% | +3.9% | -0.6% | +1.0% | +3.3% | +8.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.26 | $35.83 | +1.6% | -4.1% | -4.9% | -4.3% | -5.3% | -0.9% |
| Nov 11 | Baird | Maintains | Neutral → Neutral | — | $32.46 | $31.11 | -4.2% | +3.0% | +8.6% | +4.2% | +3.3% | +4.0% |
| Nov 10 | Leerink Partners | Maintains | Outperform → Outperform | — | $14.82 | $32.76 | +121.1% | +119.0% | +125.5% | +137.9% | +128.3% | +126.3% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.50 | $15.24 | -1.7% | -8.8% | -7.0% | -5.0% | -4.4% | +109.4% |
Recent Filings
8-K · 2.02
!! High
Cogent Biosciences, Inc. -- 8-K 2.02: Earnings Results
Cogent Biosciences released Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the quarter ending March 31, 2026.
May 5
8-K
Cogent Biosciences, Inc. -- 8-K Filing
Cogent Biosciences reported 2025 financial results and provided a business update on precision therapy development for genetically defined diseases, with no material transactions or deal announcements disclosed.
Feb 17
Data updated apr 25, 2026 2:31am
· Source: massive.com